# Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

> **NCT05181124** · PHASE1 · COMPLETED · sponsor: **Onconic Therapeutics Inc.** · enrollment: 88 (actual)

## Conditions studied

- Anti-Ulcer Agents

## Interventions

- **DRUG:** coadministration of JP-1366 and aceclofenac
- **DRUG:** coadministration of JP-1366 and meloxicam
- **DRUG:** coadministration of JP-1366 and naproxen
- **DRUG:** single-dosing of JP-1366 in Korean and Caucasian

## Key facts

- **NCT ID:** NCT05181124
- **Lead sponsor:** Onconic Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-05
- **Primary completion:** 2021-03-15
- **Final completion:** 2021-03-23
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181124, "Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05181124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*